Zhitong Financial App News, Maiwei Biotech (688062.SH) announced that the marketing application for injectable argastine α (trade name: Mypresen®) submitted by Jiangsu Taikang Biomedical Co., Ltd., a wholly-owned subsidiary of the company, was approved by the State Drug Administration. It is suitable for adult patients with non-myeloid malignant tumors to use this product to reduce the incidence of infections expressed by febrile neutropenia when receiving myelosuppressive anticancer drugs that can easily cause febrile neutropenia.

Zhitongcaijing · 05/29 10:57
Zhitong Financial App News, Maiwei Biotech (688062.SH) announced that the marketing application for injectable argastine α (trade name: Mypresen®) submitted by Jiangsu Taikang Biomedical Co., Ltd., a wholly-owned subsidiary of the company, was approved by the State Drug Administration. It is suitable for adult patients with non-myeloid malignant tumors to use this product to reduce the incidence of infections expressed by febrile neutropenia when receiving myelosuppressive anticancer drugs that can easily cause febrile neutropenia.